{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:34:53Z","timestamp":1773455693788,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate the effects of angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blockers (ARBs) administration to hypertension patients with the coronavirus disease 2019 (COVID-19) induced pneumonia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We recorded the recovery status of 67 inpatients with hypertension and COVID-19 induced pneumonia in the Raytheon Mountain Hospital in Wuhan during February 12, 2020 and March 30, 2020. Patients treated with ACEI or ARBs were categorized in group A (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922), while patients who were not administered either ACEI or ARBs were categorized into group B (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200945). We did a comparative analysis of various parameters such as the pneumonia progression, length-of-stay in the hospital, and the level of alanine aminotransferase (ALT), serum creatinine (Cr), and creatine kinase (CK) between the day when these patients were admitted to the hospital and the day when the treatment ended.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      These 67 hypertension cases counted for 33.17% of the total COVID-19 patients. There was no significant difference in the usage of drug treatment of COVID-19 between groups A and B (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). During the treatment, 1 case in group A and 3 cases in group B progressed from mild pneumonia into severe pneumonia. Eventually, all patients were cured and discharged after treatment, and no recurrence of COVID-2019 induced pneumonia occurred after the discharge. The length of stays was shorter in group A as compared with group B, but there was no significant difference (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). There was also no significant difference in other general parameters between the patients of the groups A and B on the day of admission to the hospital (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). The ALT, CK, and Cr levels did not significantly differ between groups A and B on the day of admission and the day of discharge (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>To treat the hypertension patients with COVID-19 caused pneumonia, anti-hypertensive drugs (ACEs and ARBs) may be used according to the relative guidelines. The treatment regimen with these drugs does not need to be altered for the COVID-19 patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-05821-5","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T06:06:46Z","timestamp":1611554806000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients"],"prefix":"10.1186","volume":"21","author":[{"given":"Wenjun","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengxiu","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-6928","authenticated-orcid":false,"given":"Xijing","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"issue":"2","key":"5821_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.7861\/clinmed.2019-coron","volume":"20","author":"MA Lake","year":"2020","unstructured":"Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond). 2020;20(2):124\u20137. https:\/\/doi.org\/10.7861\/clinmed.2019-coron.","journal-title":"Clin Med (Lond)."},{"issue":"3","key":"5821_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/tmi.13383","volume":"25","author":"MCG Velavan","year":"2020","unstructured":"Velavan MCG. The COVID-19 epidemic. Trop Med Int Health. 2020;25(3):278\u201380. https:\/\/doi.org\/10.1111\/tmi.13383.","journal-title":"Trop Med Int Health."},{"key":"5821_CR3","doi-asserted-by":"publisher","unstructured":"Wu F, Zhao S, Yu B, Chen Y, Wang W, Hu Y, et al. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.01.24.919183.","DOI":"10.1101\/2020.01.24.919183"},{"key":"5821_CR4","doi-asserted-by":"publisher","unstructured":"Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.01.22.914952.","DOI":"10.1101\/2020.01.22.914952"},{"issue":"10224","key":"5821_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(20)30251-8.","journal-title":"Lancet."},{"key":"5821_CR6","doi-asserted-by":"publisher","unstructured":"Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: the species and its viruses -a statement of the coronavirus study group. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.02.07.937862.","DOI":"10.1101\/2020.02.07.937862"},{"key":"5821_CR7","unstructured":"World Health Organization. WHO Director-General\u2019s remarks at the media briefing on 2019-nCoV on 11 February 2020. 2020. https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. Accessed 15 Apr 2020."},{"issue":"3","key":"5821_CR8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrmicro2090","volume":"7","author":"L Du","year":"2009","unstructured":"Du L, He Y, Zhou Y, Liu S, Zheng B, Jiang S. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev. Microbiol. 2009;7(3):226\u201336. https:\/\/doi.org\/10.1038\/nrmicro2090.","journal-title":"Nat Rev. Microbiol."},{"issue":"3","key":"5821_CR9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11427-020-1637-5.","volume":"63","author":"X Xu","year":"2020","unstructured":"Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63(3):457\u201360. https:\/\/doi.org\/10.1007\/s11427-020-1637-5.","journal-title":"Sci China Life Sci."},{"issue":"8","key":"5821_CR10","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","volume":"118","author":"VB Patel","year":"2016","unstructured":"Patel VB, Zhong JC, Grant MB, Oudi GY. Role of the ACE2\/Angiotensin 1\u20137 Axis of the Renin-Angiotensin System in Heart Failure. Circ Res. 2016;118(8):1313\u201326. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.307708.","journal-title":"Circ Res."},{"issue":"1","key":"5821_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/path.2162","volume":"212","author":"I Hamming","year":"2007","unstructured":"Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus AD, et al. The emerging role of ACE2 in physiology and disease. J Pathol. 2007;212(1):1\u201311. https:\/\/doi.org\/10.1002\/path.2162.","journal-title":"J Pathol."},{"issue":"1","key":"5821_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1152\/physrev.00023.2016","volume":"98","author":"RAS Santos","year":"2018","unstructured":"Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, et al. The ACE2\/Angiotensin-(1\u20137)\/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1\u20137). Physiol Rev. 2018;98(1):505\u201353. https:\/\/doi.org\/10.1152\/physrev.00023.2016.","journal-title":"Physiol Rev."},{"issue":"7047","key":"5821_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112\u20136. https:\/\/doi.org\/10.1038\/nature03712.","journal-title":"Nature."},{"issue":"3","key":"5821_CR14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s12250-020-00205-6","volume":"35","author":"Y Wu","year":"2020","unstructured":"Wu Y. Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury. Virol Sin. 2020;35(3):256\u20138. https:\/\/doi.org\/10.1007\/s12250-020-00205-6.","journal-title":"Virol Sin."},{"issue":"20","key":"5821_CR15","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605\u201310. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.510461.","journal-title":"Circulation."},{"issue":"4","key":"5821_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. https:\/\/doi.org\/10.1016\/S2213-2600(20)30116-8.","journal-title":"Lancet Respir Med."},{"issue":"1","key":"5821_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40779-020-0233-6.","volume":"7","author":"YH Jin","year":"2020","unstructured":"Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4. https:\/\/doi.org\/10.1186\/s40779-020-0233-6.","journal-title":"Mil Med Res."},{"issue":"1","key":"5821_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3969\/j.issn.1007-5410.2019.01.002.","volume":"24","author":"Writing Group of 2018 Chinese Guidelines for the Management of Hypertension, Chinese Hypertension League, Chinese Society of Cardiology, Chinese Medical Doctor Association Hypertension Committee, Hypertension Branch of China International Exchange and Promotive Association for Medical adn Health Care, Hypertension Branch of Chinese Geriatric Medical Associarion","year":"2018","unstructured":"Writing Group of 2018 Chinese Guidelines for the Management of Hypertension, Chinese Hypertension League, Chinese Society of Cardiology, Chinese Medical Doctor Association Hypertension Committee, Hypertension Branch of China International Exchange and Promotive Association for Medical adn Health Care, Hypertension Branch of Chinese Geriatric Medical Associarion. 2018 Chinese guidelines for the management of hypertension. Chin J Cardiovasc Med. 2018;24(1):24\u201356. https:\/\/doi.org\/10.3969\/j.issn.1007-5410.2019.01.002.","journal-title":"Chin J Cardiovasc Med"},{"key":"5821_CR19","unstructured":"National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7). 2020. http:\/\/en.nhc.gov.cn\/2020-03\/29\/c_78469.htm."},{"issue":"5","key":"5821_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475\u201381. https:\/\/doi.org\/10.1016\/S2213-2600(20)30079-5.","journal-title":"Lancet Respir Med."},{"issue":"3","key":"5821_CR21","doi-asserted-by":"publisher","first-page":"taaa041","DOI":"10.1093\/jtm\/taaa041","volume":"27","author":"JH Diaz","year":"2020","unstructured":"Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3):taaa041. https:\/\/doi.org\/10.1093\/jtm\/taaa041.","journal-title":"J Travel Med"},{"key":"5821_CR22","unstructured":"ESH Statement on COVID-19: Statement of the European Society of Hypertension (ESH) on hypertension, Renin Angiotensin System blockers and COVID-19.April 15th 2020. 2020. https:\/\/www.eshonline.org\/esh-content\/uploads\/2020\/06\/Statement-ESH-on-Hypertension-RAS-Blockers-and-COVID-19-Update-April-15-2020.pdf. Accessed 11 Feb 2020."},{"issue":"10","key":"5821_CR23","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953\u20132041. https:\/\/doi.org\/10.1097\/HJH.0000000000001940.","journal-title":"J Hypertens"},{"issue":"18","key":"5821_CR24","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032.","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2002032.","journal-title":"N Engl J Med."},{"key":"5821_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2019.104350","volume":"113","author":"R Ye","year":"2020","unstructured":"Ye R, Liu Z. ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway. Exp Mol Pathol. 2020;113:104350. https:\/\/doi.org\/10.1016\/j.yexmp.2019.104350.","journal-title":"Exp Mol Pathol."},{"issue":"4","key":"5821_CR26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/path.2987","volume":"225","author":"RM W\u00f6sten-van Asperen","year":"2011","unstructured":"W\u00f6sten-van Asperen RM, Lutter R, Specht PA, Moll GN, van Woensel JB, van der Loos CM, et al. Acute respiratory distress syndrome leads to reduced ratio of ACE\/ACE2 activities and is prevented by angiotensin-(1\u20137) or an angiotensin II receptor antagonist. J Pathol. 2011;225(4):618\u201327. https:\/\/doi.org\/10.1002\/path.2987.","journal-title":"J Pathol."},{"issue":"10223","key":"5821_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-5.","journal-title":"Lancet"},{"issue":"8","key":"5821_CR28","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875\u20139. https:\/\/doi.org\/10.1038\/nm1267.","journal-title":"Nat Med."},{"issue":"4","key":"5821_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/srep07027","volume":"13","author":"P Yang","year":"2014","unstructured":"Yang P, Gu H, Zhao Z, Wang W, Cao B, Lai C, et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep. 2014;13(4):7027. https:\/\/doi.org\/10.1038\/srep07027.","journal-title":"Sci Rep"},{"issue":"1","key":"5821_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40635-015-0044-3.","volume":"3","author":"V Zambelli","year":"2015","unstructured":"Zambelli V, Bellani G, Borsa R, Pozzi F, Grassi A, Scanziani M, et al. Angiotensin-(1\u20137) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome. Intensive Care Med Exp. 2015;3(1):44. https:\/\/doi.org\/10.1186\/s40635-015-0044-3.","journal-title":"Intensive Care Med Exp."},{"issue":"5","key":"5821_CR31","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.2353\/ajpath.2010.090565","volume":"176","author":"RM W\u00f6sten-van Asperen","year":"2010","unstructured":"W\u00f6sten-van Asperen RM, Lutter R, Specht PA, Specht PA, van Woensel JB, van der Loos CM, et al. Ventilator-induced inflammatory response in lipopolysaccharide-exposed rat lung is mediated by angiotensin-converting enzyme. Am J Pathol. 2010;176(5):2219\u201327. https:\/\/doi.org\/10.2353\/ajpath.2010.090565.","journal-title":"Am J Pathol."},{"issue":"21","key":"5821_CR32","doi-asserted-by":"publisher","first-page":"9770","DOI":"10.1073\/pnas.91.21.9770","volume":"91","author":"CT Wild","year":"1994","unstructured":"Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A. 1994;91(21):9770\u20134. https:\/\/doi.org\/10.1073\/pnas.91.21.9770.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"5821_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bbrc.2020.02.071","volume":"525","author":"Y Chen","year":"2020","unstructured":"Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020;525(1):135\u201340. https:\/\/doi.org\/10.1016\/j.bbrc.2020.02.071.","journal-title":"Biochem Biophys Res Commun"},{"key":"5821_CR34","doi-asserted-by":"publisher","unstructured":"Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020. https:\/\/doi.org\/10.1002\/ddr.21656.","DOI":"10.1002\/ddr.21656"},{"key":"5821_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coph.2017.12.002","volume":"40","author":"WSD Tan","year":"2018","unstructured":"Tan WSD, Liao W, Zhou S, Mei D, Wong WF. Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases. Curr Opin Pharmacol. 2018;40:9\u201317. https:\/\/doi.org\/10.1016\/j.coph.2017.12.002.","journal-title":"Curr Opin Pharmacol."},{"issue":"6","key":"5821_CR36","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1161\/01.HYP.0000146120.29648.36","volume":"44","author":"MJ Huentelman","year":"2004","unstructured":"Huentelman MJ, Zubcevic J, Hern\u00e1ndez Prada JA, Xiao X, Dimitrov DS, Raizada MK, et al. Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension. 2004;44(6):903\u20136. https:\/\/doi.org\/10.1161\/01.HYP.0000146120.29648.36.","journal-title":"Hypertension."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05821-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-021-05821-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05821-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T06:08:05Z","timestamp":1611554885000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-05821-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5821"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-05821-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-51043\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-51043\/v2","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,25]]},"assertion":[{"value":"29 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Dalian Central Hospital provided. The ethical approval number is YN-2020-023-01.The data used in this study was annoymised before its use. And if anyone want to check or review the raw data of this study should get the permission from me or our supervisor Dr. Zhuang Xijing.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}